- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- DISHMAN PHARMA - MYLAN (US)
DISHMAN PHARMA vs MYLAN (US) - Comparison Results
DISHMAN PHARMA 
Change
Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 DISHMAN PHARMA  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DISHMAN PHARMA Mar-16 |
MYLAN Dec-14 |
DISHMAN PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 374 | 4,254 | - | |
| Low | Rs | 129 | 2,998 | - | |
| Sales per share (Unadj.) | Rs | 197.8 | 1,456.2 | - | |
| Earnings per share (Unadj.) | Rs | 21.2 | 175.4 | - | |
| Cash flow per share (Unadj.) | Rs | 34.7 | 282.4 | - | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.8 | 0 | - | |
| Book value per share (Unadj.) | Rs | 179.9 | 723.9 | - | |
| Shares outstanding (eoy) | m | 80.69 | 378.37 | - | |
| Bonus/Rights/Conversions | - | OI | - | ||
| Price / Sales ratio | x | 1.3 | 2.5 | 51.1% | |
| Avg P/E ratio | x | 11.9 | 20.7 | 57.4% | |
| P/CF ratio (eoy) | x | 7.2 | 12.8 | 56.4% | |
| Price / Book Value ratio | x | 1.4 | 5.0 | 27.9% | |
| Dividend payout | % | 9.4 | 0 | - | |
| Avg Mkt Cap | Rs m | 20,306 | 1,371,817 | 1.5% | |
| No. of employees | `000 | 0.8 | 25.0 | 3.3% | |
| Total wages/salary | Rs m | 5,355 | 0 | - | |
| Avg. sales/employee | Rs Th | 19,252.7 | 22,039.1 | 87.4% | |
| Avg. wages/employee | Rs Th | 6,459.5 | 0 | - | |
| Avg. net profit/employee | Rs Th | 2,064.1 | 2,655.0 | 77.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 15,961 | 550,976 | 2.9% | |
| Other income | Rs m | 265 | -3,212 | -8.3% | |
| Total revenues | Rs m | 16,226 | 547,765 | 3.0% | |
| Gross profit | Rs m | 4,103 | 137,030 | 3.0% | |
| Depreciation | Rs m | 1,091 | 40,467 | 2.7% | |
| Interest | Rs m | 944 | 23,766 | 4.0% | |
| Profit before tax | Rs m | 2,334 | 69,586 | 3.4% | |
| Minority Interest | Rs m | 0 | -285 | 0.0% | |
| Prior Period Items | Rs m | 1 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 624 | 2,926 | 21.3% | |
| Profit after tax | Rs m | 1,711 | 66,374 | 2.6% | |
| Gross profit margin | % | 25.7 | 24.9 | 103.4% | |
| Effective tax rate | % | 26.7 | 4.2 | 635.5% | |
| Net profit margin | % | 10.7 | 12.0 | 89.0% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,018 | 484,381 | 2.3% | |
| Current liabilities | Rs m | 9,517 | 378,689 | 2.5% | |
| Net working cap to sales | % | 9.4 | 19.2 | 49.0% | |
| Current ratio | x | 1.2 | 1.3 | 90.5% | |
| Inventory Days | Days | 110 | 78 | 141.5% | |
| Debtors Days | Days | 35 | 107 | 32.5% | |
| Net fixed assets | Rs m | 16,304 | 127,467 | 12.8% | |
| Share capital | Rs m | 161 | 19,484 | 0.8% | |
| Net worth | Rs m | 14,516 | 273,890 | 5.3% | |
| Long term debt | Rs m | 4,189 | 409,164 | 1.0% | |
| Total assets | Rs m | 29,805 | 1,103,202 | 2.7% | |
| Interest coverage | x | 3.5 | 3.9 | 88.4% | |
| Debt to equity ratio | x | 0.3 | 1.5 | 19.3% | |
| Sales to assets ratio | x | 0.5 | 0.5 | 107.2% | |
| Return on assets | % | 8.9 | 8.2 | 109.0% | |
| Return on equity | % | 11.8 | 24.2 | 48.6% | |
| Return on capital | % | 17.5 | 13.6 | 128.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 2,786 | 72,426 | 3.8% | |
| From Investments | Rs m | -1,529 | -57,117 | 2.7% | |
| From Financial Activity | Rs m | -941 | -19,084 | 4.9% | |
| Net Cashflow | Rs m | 316 | -3,775 | -8.4% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.37 Rs / USD
Compare DISHMAN PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare DISHMAN PHARMA With: J.B.CHEMICALS ELDER PHARMA ALEMBIC LTD GSK PHARMA NOVARTIS
|
| |
Today's Market
Where Will the Two-Faced Market Go from Here?(Podcast)
The stock markets are very volatile these days. As the Tanushree Bannerjee, the co-head of research here at Equitymaster puts it, stock markets are two-faced.
Related Views On News
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Eris Lifesciences Limited (IPO)
Jun 15, 2017Exposure to high margin specialty products offers promising growth prospects.
More Views on NewsMost Popular
7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)
Feb 4, 2019Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)
Feb 7, 2019Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
Here's What the Biggest 'Rebirth of India' Investors are Doing(The 5 Minute Wrapup)
Feb 5, 2019A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.
How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)
Feb 8, 2019This is the trick to following super investors and not losing money.
Do You Have the Stomach to Survive a Small Cap Crash?(Profit Hunter)
Feb 5, 2019While selecting good businesses is relatively easy task in a bearish phase, where most people fail is in having enough patience to hold the quality stocks until recovery.
More|
| |
DISHMAN PHARMA SHARE PRICE
May 29, 2017 (Close)
TRACK DISHMAN PHARMA
- Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DISHMAN PHARMA
DISHMAN PHARMA 8-QTR ANALYSIS
COMPARE DISHMAN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.